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ABSTRACT
Background: Distal symmetric polyneuropathy (DSP) is the most common variety of neuropathy.
Since the evaluation of this disorder is not standardized, the available literature was reviewed to
provide evidence-based guidelines regarding the role of autonomic testing, nerve biopsy, and skin
biopsy for the assessment of polyneuropathy.
Methods: A literature review using MEDLINE, EMBASE, and Current Contents was performed to
identify the best evidence regarding the evaluation of polyneuropathy published between 1980
andMarch 2007. Articles were classified according to a four-tiered level of evidence scheme and
recommendations were based upon the level of evidence.
Results and Recommendations: 1) Autonomic testing should be considered in the evaluation of pa-
tients with polyneuropathy to document autonomic nervous system dysfunction (Level B). Such test-
ing should be considered especially for the evaluation of suspected autonomic neuropathy (Level B)
and distal small fiber sensory polyneuropathy (SFSN) (Level C). A battery of validated tests is recom-
mended to achieve the highest diagnostic accuracy (Level B). 2) Nerve biopsy is generally accepted as
useful in the evaluation of certain neuropathies as in patients with suspected amyloid neuropathy,
mononeuropathy multiplex due to vasculitis, or with atypical forms of chronic inflammatory demyeli-
nating polyneuropathy (CIDP). However, the literature is insufficient to provide a recommendation
regarding when a nerve biopsy may be useful in the evaluation of DSP (Level U). 3) Skin biopsy is a
validated technique for determining intraepidermal nerve fiber density andmay be considered for the
diagnosis of DSP, particularly SFSN (Level C). There is a need for additional prospective studies to
definemore exact guidelines for the evaluation of polyneuropathy. Neurology® 2009;72:1–1
GLOSSARY
AAN  American Academy of Neurology; AANEM  American Academy of Neuromuscular and Electrodiagnostic Medicine;
AAPM&R  American Academy of Physical Medicine and Rehabilitation; ART  autonomic reflex testing; BRSI  baroreflex
sensitivity index;CASS composite autonomic scoring scale;CIDP chronic inflammatorydemyelinatingpolyneuropathy;DSFN
distal small fiber neuropathy; DSP distal symmetric polyneuropathy; EDx electrodiagnosis; EFNS European Federation of
Neurological Societies;HRV heart rate variability; IAN idiopathic autonomic neuropathy; IENF intraepidermal nerve fibers;
MSNAmuscle sympathetic nerveactivity;NCSsnerveconduction studies;PGP9.5protein-gene-product9.5;PNperiph-
eral neuropathy; PRT  blood pressure recovery time; QAE  quantitative autonomic examination; QSART  quantitative
sudomotor axon reflex test; QSS  Quality Standards Subcommittee; QST  quantitative sensory testing; SFSN  small
fiber sensory polyneuropathy; TST thermoregulatory sweat testing.
Polyneuropathy is a relatively common neurologic
disorder.1 The overall prevalence is approximately
2,400 (2.4%) per 100,000 population, but in indi-
viduals older than 55 years, the prevalence rises to
approximately 8,000 (8%) per 100,000.2,3 Since
there are many etiologies of polyneuropathy, a logical
clinical approach is needed for evaluation and
management.
This practice parameter provides recommenda-
tions for the evaluation of distal symmetric polyneu-
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ropathy (DSP) based upon a prescribed review and
analysis of the peer-reviewed literature. The parame-
ter was developed to provide physicians with
evidence-based guidelines regarding the role of auto-
nomic testing, nerve biopsy, and skin biopsy for the
assessment of polyneuropathy. The diagnosis of DSP
should be based upon a combination of clinical
symptoms, signs, and electrodiagnostic criteria as
outlined in the previous case definition.1 See Mission
statement (appendix e-1 on the Neurology® Web site
at www.neurology.org) for details.
FORMATION OF EXPERT PANEL The Polyneu-
ropathy Task Force included 19 physicians with repre-
sentatives from the American Academy of Neurology
(AAN), the American Academy of Neuromuscular and
Electrodiagnostic Medicine (AANEM), and the Ameri-
can Academy of Physical Medicine and Rehabilitation
(AAPM&R). All of the task force members had exten-
sive experience and expertise in the area of polyneurop-
athy. Additionally, four members had expertise in
evidence-based methodology and practice parameter
development. Two are current members (J.D.E., G.F.),
and two are former members (G.S.G, R.G.M.) of the
Quality Standards Subcommittee (QSS) of the AAN.
The task force developed a set of clinical questions rele-
vant to the evaluation of DSP, and subcommittees were
formed to address each of these questions.
DESCRIPTION OF THE ANALYTIC PROCESS
The literature search included OVID MEDLINE
(1966 to March 2007), OVID Excerpta Medica
(EMBASE; 1980 to March 2007), and OVID Cur-
rent Contents (2000 to March 2007). The search
included articles on humans only and in all lan-
guages. The search terms selected were peripheral
neuropathy, polyneuropathy, and distal symmetric
polyneuropathy. These terms were cross-referenced
with the terms diagnosis, electrophysiology, auto-
nomic testing, nerve biopsy, and skin biopsy.
Panel experts were asked to identify additional ar-
ticles missed by the initial search strategy. Further,
the bibliographies of the selected articles were re-
viewed for potentially relevant articles.
Subgroups of committee members reviewed the
titles and abstracts of citations identified from the
original searches and selected those that were poten-
tially relevant to the evaluation of polyneuropathy.
Articles deemed potentially relevant by any panel
member were also obtained.
Each potentially relevant article was subsequently
reviewed in entirety by at least three panel members.
Each reviewer graded the risk of bias in each article
by using the diagnostic test classification-of-evidence
scheme (appendix e-2). In this scheme, articles at-
taining a grade of Class I are judged to have the low-
est risk of bias, and articles attaining a grade of Class
IV are judged to have the highest risk of bias. Dis-
agreements among reviewers regarding an article’s
grade were resolved through discussion. Final ap-
proval was determined by the entire panel. The
AAN’s method for determining the strength of rec-
ommendation was used (appendix e-3).
The QSS (AAN; appendix 1), the Practice Issues
Review Panel (AANEM; appendix 2), and the Practice
Guidelines Committee (AAPM&R; appendix 3) re-
viewed and approved a draft of the article. The draft was
next sent to members of the AAN, AANEM, and
AAPM&R for further review and then to Neurology®
for peer review. Boards of the AAN, AANEM, and
AAPM&R reviewed and approved the final version of
the article. At each step of the review process, external
reviewers’ suggestions were explicitly considered. When
appropriate, the expert panel made changes to the
document.
ANALYSIS OF EVIDENCE The search yielded
1,045 references with abstracts. After reviewing titles
and abstracts, 106 articles were reviewed and classified.
Role of clinical autonomic testing in the evaluation of
polyneuropathy. Autonomic nervous system dysfunc-
tion occurs in several phenotypes. It may occur as
one component of a generalized polyneuropathy
such as DSP of diabetes. Such polyneuropathies are
usually diagnosed by a combination of neuropathic
symptoms, decreased or absent ankle reflexes, de-
creased distal sensation, distal muscle weakness or at-
rophy, and abnormal nerve conduction studies
(NCSs).1 The majority of these features constitute
evidence of “large fiber” sensory and motor involve-
ment. However, signs of autonomic nervous system
involvement may also constitute findings indicative
of DSP. In DSP with autonomic involvement, the
most common clinical findings are abnormalities of
sweating and circulatory instability in the feet.1,3
A second phenotype is that of an autonomic neu-
ropathy such as in amyloidosis and autoimmune au-
tonomic neuropathy, where autonomic nerves are
affected disproportionately relative to somatic
nerves.4 In these neuropathies, autonomic fibers can
be affected in isolation and their involvement may
precede somatic fiber involvement.5
A third relatively common phenotype is distal
small fiber sensory polyneuropathy (SFSN), which
can manifest as burning pain affecting the feet, often
with allodynia and sometimes with erythromelalgia
(red hot and painful skin). Involvement of auto-
nomic and somatic C fibers usually occurs concur-
rently in small fiber polyneuropathy.5
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What is the usefulness of clinical autonomic testing
in the evaluation of polyneuropathy, and which tests have
the highest sensitivity and specificity? Currently available
autonomic tests can provide indices of cardiovagal,
adrenergic, and postganglionic sudomotor function.
As such, they provide indices for both parasympa-
thetic and sympathetic autonomic function. Heart
rate variability testing is a simple and reliable test of
cardiovagal function. It detects the presence of dia-
betic polyneuropathy with nearly the same sensitivity
as NCSs (Class II).6 Specificity is high (97.5%) for
identifying parasympathetic deficits if the recom-
mended age-controlled values are used (Class II).7 In-
trinsic cardiac disease can affect the results of this
test, and this possibility must be considered in the
interpretation.
Cardiovagal function can be evaluated using dif-
ferent indices in the time and frequency domains.8
There is no compelling evidence that one method is
better than another or that the use of multiple indices
confers any advantage. Heart rate variability to deep
breathing is the most widely used test of cardiovagal
function and has a specificity of approximately 80%
(Class II).9
The vagal component of the baroreflex can be
evaluated by quantitating the heart period response
to induced changes in BP. A well-studied test is the
modified Oxford method.10 The test consists of an
evaluation of heart period responses to induced in-
creases and decreases in arterial BP. The increase is
evoked by IV phenylephrine and decrease by nitro-
prusside in incremental doses. Baroreflex sensitivity
is defined by the slope of the heart period to BP
relationship. Linearity is required (R  0.85). The
advantage of this test is that it evaluates vagal barore-
flex sensitivity; however, the disadvantage is that the
test is invasive and not widely performed. Approxi-
mation of this method is possible by relating heart
period alterations to changes in BP induced by the
Valsalva maneuver.11 The sensitivity and specificity
of invasive and noninvasive tests of baroreflex func-
tion are high, but these tests are not generally used in
the study of neuropathy since their value is consid-
ered only additive to current tests of cardiovagal
function (Class II).4,9,12,13
Thermoregulatory sweat testing (TST) is a sensi-
tive test of sudomotor function that utilizes an indi-
cator substance whose color changes upon exposure
to sweat.14,15 The test results can be semiquantitated
by estimating the percentage of skin surface that is
anhidrotic. Since the test is tedious, messy, and time-
consuming, it is not routinely done. Additionally,
TST is not able to distinguish between postgangli-
onic, preganglionic, and central lesions.14,15 The
most quantitative test of sudomotor function is the
T
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quantitative sudomotor axon reflex test (QSART).16
QSART is mediated by impulses traveling anti-
dromically then orthodromically along the post-
ganglionic sympathetic sudomotor axon. QSART
can detect distal sudomotor loss with a sensitivity
of 75–90% (Class III).7,17-19 Several studies have
demonstrated that QSART can determine sudomotor
abnormalities with relatively high sensitivity and speci-
ficity in many types of polyneuropathies (Class II
and III).4-7,16,17,19-21 In three Class III studies,
QSART was shown capable of detecting distal
small fiber polyneuropathy with a sensitivity of
75%.17-19
Skin vasomotor reflexes assessed by monitoring
skin blood flow using laser Doppler flowmeter have
not been well studied. Limited data from one Class
III study using this technique demonstrated an unac-
ceptably large coefficient of variation.22
Analysis of the available Class II and III studies on
autonomic testing indicates that a combination of
autonomic reflex screening tests provides distinct ad-
vantages over single modality methods (table). The
composite autonomic scoring scale (CASS), which
includes QSART, orthostatic blood pressure, heart
rate response to tilt, heart rate response to deep
breathing, the Valsalva ratio, and beat-to-beat blood
pressure measurements during phases II and IV of
the Valsalva maneuver, tilt, and deep breathing, pro-
vides a useful 10-point scale of autonomic function
(Class II).4,9 In a study of 78 patients with graded
autonomic failure obtained by selecting approximately
equal numbers of patients with multiple system atro-
phy, Parkinson disease, autonomic neuropathies, and
idiopathic peripheral neuropathies, this combination of
tests provided a noninvasive, sensitive, specific, and re-
producible methodology for grading the degree of auto-
nomic dysfunction (Class II).9
Conclusions. Autonomic testing is probably useful
in documenting autonomic nervous system involve-
ment in polyneuropathy (Class II and III). The sen-
sitivity and specificity vary with the particular test.
The utilization of the combination of autonomic re-
flex screening tests in the CASS probably provides
the highest sensitivity and specificity for document-
ing autonomic dysfunction (Class II).
Recommendations. Autonomic testing should be
considered in the evaluation of patients with poly-
neuropathy to document autonomic nervous system
involvement (Level B). Autonomic testing should be
considered in the evaluation of patients with sus-
pected autonomic neuropathies (Level B) and may be
considered in the evaluation of patients with sus-
pected distal SFSN (Level C). The combination of
autonomic screening tests in the CASS should be
considered to achieve the highest diagnostic accuracy
(Level B).
Role of nerve biopsy in the evaluation of polyneurop-
athy. Nerve biopsy is generally accepted as useful in
the diagnosis of inflammatory diseases of nerve such
as vasculitis, sarcoidosis, CIDP, infectious diseases
such as leprosy, or infiltrative disorders such as tumor
or amyloidosis.3 Nerve biopsy is most valuable in
mononeuropathy multiplex or suspected vasculitic
neuropathy. There are no studies regarding the role
of nerve biopsy in the evaluation of DSP although on
occasion the above noted diseases may present in that
fashion.
What is the usefulness of nerve biopsy in determining the
etiology of distal symmetric polyneuropathy? Out of 50
articles judged to be relevant, no article attained a
grade greater than Class IV. Most of the articles dis-
cussed the nerve biopsy findings in specific diseases, the
clinical suspicion of which had prompted the
biopsy.23-34 No article provided guidance regarding
when to perform a nerve biopsy in the evaluation of
DSP.
Conclusions. There is no evidence to support or re-
fute a conclusion regarding the role of nerve biopsy
in the evaluation of DSP (Class IV).
Recommendations. No recommendations can be
made regarding the role of nerve biopsy in determin-
ing the etiology of DSP (Level U).
Role of skin biopsy in the evaluation of polyneurop-
athy. Skin biopsy is being increasingly used to evalu-
ate patients with polyneuropathy. The most
common technique involves a 3 mm punch biopsy of
skin from the leg. After sectioning by microtome, the
tissue is immunostained with anti-protein-gene-
product 9.5 (PGP 9.5) antibodies and examined
with immunohistochemical or immunofluorescent
methods. This staining allows for the identification
and counting of intraepidermal nerve fibers (IENF).
PGP 9.5 immunohistochemistry has been validated
as a reliable method for IENF density determination
with good intra- and interobserver reliability in nor-
mal controls and patients with DSP. 35-38
In March 2005, the European Federation of Neu-
rological Societies (EFNS) published a guideline on
the use of skin biopsy in peripheral neuropathy.35
This comprehensive review focused on the technical
aspects of skin biopsy as well as normative data and
correlations with other clinical, physiologic, and
pathologic tools. The EFNS concluded that skin bi-
opsy is a safe, validated, and reliable technique for the
determination of IENF density. The major conclu-
sion was that skin biopsy (IENF density) was diag-
nostically efficient at distinguishing polyneuropathy
patients (including small fiber neuropathy) from
normal controls. The EFNS guideline also reviewed
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the literature on IENF morphologic changes such as
axonal swellings as a measure of distal symmetric
polyneuropathy.35,39,40 The EFNS concluded that ax-
onal swellings may be predictive of progression of
polyneuropathy but further studies were needed to
determine their diagnostic accuracy.35
What is the usefulness and diagnostic accuracy of skin
biopsy in the evaluation of polyneuropathy? Beyond dis-
tinguishing asymptomatic normal controls from
polyneuropathy patients, one clinical question not
addressed by the EFNS guideline was the diagnostic
accuracy of skin biopsy in distinguishing symptom-
atic patients with polyneuropathy from symptomatic
patients without polyneuropathy. For example, in
patients with painful feet, would skin biopsy accu-
rately distinguish patients with polyneuropathy from
patients with other conditions causing painful feet?
To address this separate question, a subgroup of
the Polyneuropathy Task Force (J.D.E., R.A.L.,
D.H., G.L., M.P., and G.S.G.) independently re-
viewed the literature regarding the diagnostic accu-
racy of skin biopsy in DSP and in the SFSN form of
DSP. To be considered for review, studies needed to
determine IENF density in patients with and with-
out polyneuropathy. Furthermore, the data from
studies had to be presented in such a way as to allow
calculation of the sensitivity and specificity of skin
biopsy for polyneuropathy.
Nine studies met inclusion criteria.36,39-40,e1-e6
One was a prospective cohort survey of patients pre-
senting with bilateral painful feet and normal
strength, but skin biopsy was done only in those with
normal NCS.e1 Patients with reduced IENF density
and normal NCS were assumed to have painful small
fiber neuropathies. However, the study did not com-
pare the results of the IENF density to an indepen-
dent reference standard to confirm the presence of
small fiber neuropathy. Thus, for the purposes of de-
termining the diagnostic accuracy of skin biopsy for
polyneuropathy, this study was graded Class IV.
The remaining studies employed a case-control
design.36,39,40,e2-e6 In these studies, the investigators
performed skin biopsies on patients with established
polyneuropathy and normal controls. No study in-
cluded patients with conditions causing lower ex-
tremity pain or sensory complaints that might be
confused with polyneuropathy. Thus, all studies had
potential spectrum bias. Following the evidence clas-
sification scheme for studies of diagnostic accuracy,
all of these studies were graded Class III.
All of the case control studies showed a significant
reduction in IENF density in polyneuropathy pa-
tients as compared to controls.36,39,40,e2-e6 The sensi-
tivity of decreased IENF density for the diagnosis of
polyneuropathy was moderate to good (range 45 to
90%). The specificity of normal IENF density for
the absence of polyneuropathy was very good (range
95 to 97%). Thus, the absence of reduced IENF den-
sity (using the clinical impression as the diagnostic ref-
erence standard) would not “rule out” polyneuropathy,
but the presence of reduced IENF density would im-
portantly raise the likelihood of polyneuropathy.
The form of DSP for which IENF assessment is
particularly diagnostically attractive is SFSN for the
following reasons: 1) IENF are the nerve terminals of
somatic unmyelinated C fibers, which are hypothe-
sized to be predominantly affected in SFSN. 2)
There has been a lack of a direct objective measure of
small fiber sensory nerves since objective measures of
large fiber function (e.g., NCS) are by most defini-
tions normal in SFSN.e7 3) Patients in whom SFSN
is clinically suspected manifest with symptoms of
small fiber sensory dysfunction (e.g., tingling, numb-
ness, and neuropathic pain) but few objective signs,
making it difficult to diagnose and to distinguish SFSN
from non-neurologic causes of sensory complaints.e7
Since no validated objective gold standard exists
for the diagnosis of SFSN, the authors considered
whether demonstration of a pathologic lesion (small
sensory fiber pathology on skin biopsy) should be the
de facto diagnostic standard or whether a clinical im-
pression of SFSN should be the independent reference
standard. For the purposes of this parameter, a clinical
impression of SFSN was adopted as the independent
reference standard for calculation of sensitivity and
specificity of IENF density in the detection of SFSN.
In order to assess the diagnostic accuracy of IENF
density assessment for SFSN, the literature was sur-
veyed for studies assessing IENF density in subjects
with clinically suspected SFSN (symptoms or symp-
toms and signs of DSP but with normal NCS) and
controls where the diagnostic accuracy of IENF den-
sity for clinically defined SFSN could be determined.
Four Class III studies met these criteria.e6,e8-e10 The
sensitivity of IENF density assessment at the ankle
for DSP with normal NCS was 58% (20% for sub-
jects with symptoms but no signs of SFSN; 100% for
subjects with symptoms and signs of SFSN),e8
90%,e6 and 24%.e9 In these studies, the specificity of
the test ranged from 95% to 97.5%.e6,e8,e9 The other
case control study found that among patients with
symptoms of SFSN and an abnormal pinprick exam-
ination in the feet, but normal ankle reflexes, normal
vibration sensibility, and normal NCS, an IENF
density of 8 fibers/mm at the dorsal foot provided
a sensitivity of 88%, a specificity of 91%, a positive
predictive value of 0.9, and a negative predictive
value of 0.83 for the diagnosis of SFSN.e10
Conclusions. IENF density assessment using PGP
9.5 immunohistochemistry is a validated, reproduc-
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ible marker of small fiber sensory pathology. Skin
biopsy with IENF density assessment is possibly use-
ful to identify DSP which includes SFSN in symp-
tomatic patients with suspected polyneuropathy
(Class III).
Recommendations. For symptomatic patients with
suspected polyneuropathy, skin biopsy may be con-
sidered to diagnose the presence of a polyneurop-
athy, particularly SFSN. (Level C)
RECOMMENDATIONS FOR FUTURE RESEARCH
This comprehensive review reveals several weaknesses
in the current approach to the evaluation of polyneu-
ropathy and highlights opportunities for research.
• Autonomic testing. Autonomic testing can
with a high degree of accuracy document auto-
nomic system dysfunction in polyneuropathy.
This is particularly relevant to small fiber poly-
neuropathy and the autonomic neuropathies.
Research is necessary to determine whether the
documentation of autonomic abnormalities is
important in modifying the evaluation and
treatment of polyneuropathy. Specific tests
such as QSART can document small fiber (i.e.,
sudomotor axon) loss with a high degree of sen-
sitivity, making the test useful to confirm the
diagnosis of small fiber polyneuropathy. Since
skin biopsy with determination of IENF den-
sity can also document small fiber loss, there is
a need for studies that compare and correlate
the two techniques.
• Nerve biopsy. There are no studies of nerve bi-
opsy in the evaluation of DSP. Although it
would be useful to know the outcome of well-
designed prospective studies in this area, it is
unlikely that such studies will be done.
• Skin biopsy. Skin biopsy with determination of
IENF density is a technique that has come of
age for the objective documentation of small
fiber loss. This technique provides a unique op-
portunity for research in different varieties of
neuropathy. Further studies are needed to char-
acterize the diagnostic accuracy of skin biopsy
in distinguishing patients with suspected poly-
neuropathy, particularly SFSN, from patients
with sensory complaints or pain unrelated to
peripheral neuropathy. Prospective studies with
appropriate “other disease” controls should be
done to assess the sensitivity, specificity, and
predictive values of IENF density measurement
to identify SFSN in patients with lower extrem-
ity pain or sensory complaints. A predeter-
mined independent reference standard for the
diagnosis of SFSN should be specifically stated
in such studies.
• A case definition of SFSN should be developed.
Investigators need to determine whether this
case definition should be based upon clinical
criteria, pathologic criteria (e.g., skin biopsy),
or a combination of clinical, paraclinical, and
pathologic criteria.
• The diagnostic accuracy of morphologic
changes (e.g., axonal swellings) in the diagnosis
of SFSN vs healthy controls and disease con-
trols needs to be better defined.
• Studies exploring other uses for skin biopsy be-
yond identification and quantification of DSP
and SFSN have been reported and should be
further explored. Biopsies of glabrous skin and
dermal skin include myelinated nerve fibers,
and have been shown to have potential utility
in the diagnosis of immune-mediated neuropa-
thies, Charcot-Marie-Tooth, and related dis-
eases.e2 Other studies have employed skin
biopsy for detection or monitoring of leprosy,
hereditary amyloidosis, vasculitic neuropathy,
and Fabry disease.e11-e14 Additional studies are
required to determine the usefulness of skin bi-
opsy in the diagnosis and monitoring of these
and other varieties of neuropathy.
• Serial IENF density measurements and IENF
regenerative capacity are being studied and used
as outcome measures in therapeutic trials.e15,e16
Further studies are needed to validate and deter-
mine the value of skin biopsy for this purpose.
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